Publicaciones en colaboración con investigadores/as de University of Texas Health Science Center at San Antonio (101)

2024

  1. Comparison of Patient Health Questionnaire-9, Edinburgh Postnatal Depression Scale and Hospital Anxiety and Depression – Depression subscale scores by administration mode: An individual participant data differential item functioning meta-analysis

    Journal of Affective Disorders, Vol. 361, pp. 674-683

  2. Correction to: Optical coherence tomography in coronary atherosclerosis assessment and intervention (Nature Reviews Cardiology, (2022), 19, 10, (684-703), 10.1038/s41569-022-00687-9)

    Nature Reviews Cardiology

  3. Current recommendations for procedure selection in class I and II obesity developed by an expert modified Delphi consensus

    Scientific reports, Vol. 14, Núm. 1, pp. 3445

2023

  1. Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (Intensive Care Medicine, (2023), 49, 6, (615-632), 10.1007/s00134-023-07033-8)

    Intensive Care Medicine

  2. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    Intensive Care Medicine, Vol. 49, Núm. 6, pp. 615-632

  3. ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia

    European Respiratory Journal, Vol. 61, Núm. 4

2022

  1. Cortical activity involved in perception and imagery of visual stimuli in a subject with aphantasia. An EEG case report

    Neurocase, Vol. 28, Núm. 4, pp. 344-355

  2. Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial

    Journal of Clinical Oncology, Vol. 32

  3. Melatonin as an Anti-Aging Therapy for Age-Related Cardiovascular and Neurodegenerative Diseases

    Frontiers in Aging Neuroscience, Vol. 14

  4. Optical coherence tomography in coronary atherosclerosis assessment and intervention

    Nature Reviews Cardiology, Vol. 19, Núm. 10, pp. 684-703

  5. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

  6. Secukinumab demonstrates efficacy, safety, and tolerability upon administration by 2 ml autoinjector in adult patients with plaque psoriasis: 52-week results from MATURE, a randomized, placebo-controlled trial

    Dermatologic Therapy, Vol. 35, Núm. 3

2021

  1. Aspiration Risk Factors, Microbiology, and Empiric Antibiotics for Patients Hospitalized With Community-Acquired Pneumonia

    Chest, Vol. 159, Núm. 1, pp. 58-72

  2. Global guideline for the diagnosis and management of rare yeast infections: an initiative of the ECMM in cooperation with ISHAM and ASM

    The Lancet Infectious Diseases, Vol. 21, Núm. 12, pp. e375-e386

  3. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  4. Understanding the host in the management of pneumonia: An official American thoracic society workshop report

    Annals of the American Thoracic Society, Vol. 18, Núm. 7, pp. 1087-1097

2020

  1. Combination of Rigid and Nonrigid Fixation Versus Nonrigid Fixation for Bilateral Mandibular Fractures: A Multicenter Randomized Controlled Trial

    Journal of Oral and Maxillofacial Surgery, Vol. 78, Núm. 10, pp. 1781-1794

  2. Correction to: Atypical pathogens in hospitalized patients with community-acquired pneumonia: a worldwide perspective (BMC Infectious Diseases, (2018), 18, 1, (677), 10.1186/s12879-018-3565-z)

    BMC Infectious Diseases

  3. Effect of platelet storage duration on clinical outcomes and incremental platelet change in critically ill children

    Transfusion, Vol. 60, Núm. 12, pp. 2849-2858

  4. Standard anthracycline based versus docetaxel-capecitabine in early high clinical and/or genomic risk breast cancer in the EORTC 10041/BIG 3-04 MINDACT phase III trial

    Journal of Clinical Oncology, Vol. 38, Núm. 11, pp. 1186-1197